ONCOPEP

Oncopep was initially formed to commercialize the technology developed by Drs. Kenneth Anderson, Jooeun Bae, and Nihkil Munshi, world-renowned hematologic oncologists at the Dana-Farber Cancer Institute, one of the leading cancer institutes in the world... OncoPep is developing immunotherapeutics to prevent the progression of cancer, extend survival, and restore the quality of life for patients by attacking cancer from multiple angles... We are assembling a pipeline of investigational cancer vaccines and cell therapies to train patients' immune systems to attack cancer. Our lead investigational vaccine, PVX-410, is being tested in clinical trials in SMM and TNBC to evaluate its potential as an important component in future immunotherapy regimens for the treatment of cancer.

Also known as: OncoPep Korea, OncoPep, Inc.

Primary location: Cambridge United States